Alcidion Expands Partnership with NextGate to UK Market

Alcidion LtdSmart health tech provider Alcidion Group Limited (ASX:ALC) has announced an expansion of its reseller agreement with NextGate to include the UK and Ireland.

In 2018, MKM Health (which was acquired by Alcidion in 2018) signed an agreement to resell NextGate's market leading Enterprise Master Patient Index (EMPI) and Provider Registry solutions in Australia and New Zealand. Following a successful two-year relationship, this agreement has now been extended to also include the UK and Ireland.

NextGate is the global leader in healthcare enterprise identification, helping healthcare organisations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data.

Alcidion's reseller agreement with NextGate has resulted in two significant state-wide contracts in Australia. The Queensland Health Referral Service Directory based on the Provider Index was delivered by Alcidion working closely with NextGate. For the Victorian Department of Health and Human Services Unique Patient Identification program, Alcidion supported NextGate in delivery of its EMPI capability.

The expansion of the agreement to the UK and Ireland will further strengthen Alcidion's ability to support NHS trusts, health boards and region wide integrated care systems. The news follows the Alcidion's formal launch this summer of its Miya Precision product as the first smart clinical asset for the NHS.

Lynette Ousby, UK General Manager of Alcidion, said: "With the current focus in the NHS on consolidating clinical systems across regions, the ability to include the offering of NextGate solutions to complement our Miya Precision capability, establishes a true enterprise approach to healthcare delivery."

Alcidion's Miya Precision presents the NHS with an opportunity to move beyond static electronic records to technology that engages healthcare professionals. Early adopters are using the platform to orchestrate information across disparate systems using modern technology from Alcidion based on the FHIR standard and to establish smart clinical engagement supported by tailored clinical decision support.

With the ability to allow NHS organisations to use data to automate routine tasks, care plans and pathways, Miya Precision is being seen as a way to realise more value from electronic patient record investments and to provide a technology orchestration layer in trusts and for entire regions.

The addition of the NextGate Patient and Provider Registries, which are built on the MatchMetrix® master identity platform, will extend that capability to effectively manage identity for both patients and healthcare providers.

"We are delighted to expand our partnership with Alcidion to facilitate a modernised NHS infrastructure where patients are accurately identified and consistently matched to their health and social care data," said Andy Aroditis, CEO of NextGate. "Together, Alcidion and NextGate are delivering innovative interoperable solutions that maximise the quality, efficiency and coordination of care."

Alcidion Managing Director, Kate Quirke commented: "I am delighted that we can now expand our success implementing the NextGate solution in Australia to the UK. The combination of our service delivery and domain expertise with the powerful capabilities of MatchMetrix creates a compelling opportunity for the health sector to establish first class identity management."

About NextGate

With over 200 customers in six countries, NextGate is the global leader in healthcare enterprise identification. Committed to helping organizations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data, our full suite of identity matching solutions connects the entire healthcare ecosystem to drive critical improvements in quality, efficiency and safety. NextGate’s market leading EMPI currently manages 300 million lives and is deployed by the nation’s most successful healthcare systems and health information exchanges.

About Alcidion

Alcidion (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

Most Popular Now

AI Catches One-Third of Interval Breast …

An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published...

Great plan: Now We need to Get Real abou…

The government's big plan for the 10 Year Health Plan for the NHS laid out a big role for delivery. However, the Highland Marketing advisory board felt the missing implementation...

Researchers Create 'Virtual Scienti…

There may be a new artificial intelligence-driven tool to turbocharge scientific discovery: virtual labs. Modeled after a well-established Stanford School of Medicine research group, the virtual lab is complete with an...

From WebMD to AI Chatbots: How Innovatio…

A new research article published in the Journal of Participatory Medicine unveils how successive waves of digital technology innovation have empowered patients, fostering a more collaborative and responsive health care...

New AI Tool Accelerates mRNA-Based Treat…

A new artificial intelligence (AI) model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various...

Can Amazon Alexa or Google Home Help Det…

Computer scientists at the University of Rochester have developed an AI-powered, speech-based screening tool that can help people assess whether they are showing signs of Parkinson’s disease, the fastest growing...

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

The Human Touch of Doctors will Still be…

AI-based medicine will revolutionise care including for Alzheimer’s and diabetes, predicts a technology expert, but it must be accessible to all patients. Healing with Artificial Intelligence, written by technology expert Daniele...